Form 4: ImmunityBio Director Linda Maxwell Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Linda Maxwell was granted 65,600 stock options in ImmunityBio, Inc. with a strike price of $7.25.
Summary
- Director Linda Maxwell received a grant of 65,600 stock options for ImmunityBio, Inc. (IBRX) common stock.
- The options have an exercise price of $7.25 per share.
- The grant date for these options is June 9, 2026.
- The options are set to expire on June 9, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- The grant is subject to a one-year vesting schedule, encouraging retention.
Negatives
- The issuance of new stock options results in potential future dilution for existing shareholders.
Risks
- Vesting is contingent upon the director remaining a Service Provider to the company.
- Market volatility could impact the future value of the granted options.
Future Outlook
The options vest in full on the earlier of June 9, 2027, or the day before the next annual meeting of stockholders, provided the director remains a service provider.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure leadership remains incentivized to achieve long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of equity-based compensation for directors is consistent with standard corporate governance practices for mid-cap biotech firms.
- The one-year cliff vesting period is a common retention mechanism used by companies like ImmunityBio to align director tenure with annual shareholder cycles.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Linda Maxwell authorized several individuals to file SEC reports on her behalf. | 2025-10-29 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 9, 2027, or the date preceding the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2025-10-29 | Date of Power of Attorney execution. |
| 2026-06-09 | Date of option grant and earliest transaction. |
| 2027-06-09 | Vesting date for the stock options. |
| 2036-06-09 | Expiration date of the stock options. |
Keywords
ImmunityBio, IBRX, Director Compensation, Stock Options, SEC Form 4, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.